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Figure 1  
CT images of PNEN with pathological grade, G1, G2 and G3 at artery phase of dynamic CT. Pathological 
grade 1 (1A) is very high density, and grade 3 (1C) is very low. Grade 2 (1B) is intermediate between grade 
1 and 3. Each arrow indicates the tumor.  
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Figure 2  
The relationship between pathological grade (G1+G2, G3) and CT ratio. Between G1+G2 and G3, CT ratio 
has significant difference (p=0.0003).  
254x190mm (96 x 96 DPI) 
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Figure 3  
Three examples of CD31 immunostaining of PNEN are shown. Brownish area is CD31 positive area. 
Figure 3A  
Immunohistochemical staining of CD31 in G1 PNEN. Intratumoral microvascular density (MVD) is high, and 
the microvessel is long.  
Figure 3B  
Immunohistochemical staining of CD31 in G2 PNEN. The MVD of G2 is lower than that of G1, and the length 
of microvessel is shorter than that of G1.  
Figure 3C  
Immunohistochemical staining of CD31 in G3 PNEN. MVD is very low and almost all microvessels are not 
seen in G3.  
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Page 4 of 31Journal of Gastroenterology and Hepatology
For Peer Review
Figure 4  
MVD has a significant correlation with CT ratio in arterial phase (r=0.83, p<0.0001) 
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Figure 5  
MVD has a significant correlation with pathological grade (p=0.0074) 
254x190mm (96 x 96 DPI) 
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Supplemental figure 1  
The relationship between pathological grade (G1, G2, G3) and CT ratio. Between G1 and G2; G2 and G3; 
and G3 and G1, CT ratio has significant difference (p<0.05).  
254x190mm (96 x 96 DPI) 
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Supplemental figure 2  
Receiver operating characteristic (ROC) curve for prediction of G3 with CT ratio. The area under the receiver 
operating characteristic curve (AUROC) is 0.97. The cut-off value of CT ratio between the G1, G2, and G3 
determined by the ROC analysis was 0.75.  
254x190mm (96 x 96 DPI) 
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Table 1 Clinical and histological characteristics of patients 
All cases (n = 39) 
Male/Female 15/24 
Age (mean ± SD) 55 ± 14 
MEN1/VHL 3/2 
Position 
Head /Body/Tail 20/12/7 
Tumor diameter (mm) (mean ± SD) 29 ± 25 
Tumor type 
Functional/Non-functional 6/33 
Hormonal type 
Insulinoma 
Gastrinoma 
Glucagonoma 
3 
2 
1 
Pathological classification 
G1/G2/G3 24/9/6 
TNM classification 
I/II/III/IV 16/11/3/9 
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Supplemental Figure 4  
The relationship between pathological grade (G1+G2, G3) and tumor size. The G3 tumors are larger than 
tumors of G1 and G2 (p < 0.05).  
254x190mm (96 x 96 DPI) 
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Abstract 
Background and Aim: Pathological grading is important in defining the therapeutic 
strategy in pancreatic neuroendocrine neoplasm (PNEN), but is difficult for 
unresectable cases. Endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) 
is useful in the diagnosis of PNEN, but its usefulness for pathological grading is not 
well established. No studies have examined the diagnostic ability of dynamic computed 
tomography (CT) for pathological grading of PNEN. We investigated the usefulness of 
EUS-FNA and dynamic CT in the diagnosis and pathological grading of PNEN. 
Methods: In this retrospective study, 39 PNEN patients finally diagnosed via EUS-FNA 
and/or surgical resection underwent dynamic CT. Pathological samples were diagnosed 
based on WHO2010; staging was based on the ENETS classification. The proportion of 
the quantification value in the tumor to the pancreatic parenchyma in arterial phase was 
defined as the CT ratio. Immunohistochemical staining with CD31 was performed to 
evaluate microvessel density (MVD). We evaluated the relationship between 
pathological grade, CT ratio, and MVD. 
Results: By using EUS-FNA, 35 of 39 (90%) cases were diagnosed as PNEN. As for 
pathological grade, 15 of 35 (43%) cases could be identified correctly. CT ratio could 
predict pathological grade 3 disease. The sensitivity, specificity, and diagnostic accuracy 
were 100%, 94%, and 95%. MVD was significantly correlated with CT ratio (r = 0.83, p 
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< 0.0001) and pathological grade (p = 0.0074). 
Conclusions: CT ratio has a relationship with pathological grade in PNEN, which 
would help decide therapeutic strategy in unresectable cases and cases in which 
pathological grading is difficult. 
Key words: dynamic CT, microvessel density, pancreatic neuroendocrine neoplasm, 
pathological grade, WHO2010 
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Introduction 
Pancreatic neuroendocrine neoplasms (PNENs) are rare tumors derived from the 
hormone-producing cells in the pancreas islet of Langerhans and precursors in the 
ductal epithelium.
1
 The crude annual incidence per 100,000 is 5.3 in the United States
1,2
and 2.2 in Japan.
3
 PNEN is commonly regarded as a low- to intermediate-grade
neuroendocrine neoplasm.
4
 However, in some patients, especially those with distant
metastasis, the condition progressively worsens. Yao et al. reported that the median 
survival time in regional stage and distant stage was 77 months and 24 months, 
respectively, from SEER registry data.
4,5
The World Health Organization (WHO) defined the pathological classification of 
PNEN in the WHO2010 grading system, in which PNEN is classified into Grade 1 (G1), 
Grade 2 (G2), and Grade 3 (G3) according to the mitotic activity and Ki-67 labeling 
index.
6
 This classification is commonly used and is useful for the prognosis of
PNEN.
2,7,8
 The WHO2010 grading system is also very useful for determining a
therapeutic strategy. 
Although the prognosis after curative resection for patients with PNEN is relatively 
fair, the prognosis for unresectable patients is poor.
5
 For the patients with unresectable
PNEN, therapeutic options are transcatheter arterial chemoembolization (TACE), 
radiofrequency ablation (RFA), somatostatin analogue, sunitinib, streptozocin, oral 
inhibitor of mammalian target of rapamycin (mTOR), and peptide receptor-targeted 
radiotherapy (PRRT).
9
 These are particularly applicable in the unresectable G1 and G2
cases.
9–11
 However, in cases of unresectable neuroendocrine carcinoma (NEC),
combination chemotherapy using platinum plus etoposide is recommended as per 
NCCN and ESMO guidelines.
9,12
 In Japan, combination chemotherapy using platinum
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plus irinotecan is also used.
13
 However, no satisfactory survival rates have been
achieved in these cases yet.
9,13
 In this way, there is significant difference between G1,
G2, and G3 cases on therapeutic strategy and survival duration. Therefore, the 
identification of pathological grade is very important for unresectable case to be treated 
appropriately. 
Hasegawa et al. reported the usefulness of endoscopic ultrasound (EUS)-guided fine 
needle aspiration (FNA) for the diagnosis of PNEN
14
; however, the usefulness of
EUS-FNA for pathological grading is still not well established.
15,16
 The operation
sample or enough volume of biopsy sample are needed for accurate pathological 
grading. However, it is sometimes difficult to obtain a sufficient sample for unresectable 
cases. Other modalities for prediction of pathological grade may be helpful to decide the 
therapeutic strategy. 
Many reports stated that the majority of PNENs are enhanced clearly following 
intravenous injection of contrast medium. In particular, tumor-to-pancreas contrast is 
usually greatest in arterial phase.
17–20
 Inversely, it is reported that characteristic finding
of small cell cancer of pancreas takes on a slight enhanced effect with CT using contrast 
agent.
21
 However, there is no detailed report about the correlation between pathological
grade based on WHO2010 and quantitative evaluation of the enhancement on enhanced 
CT. 
Angiogenesis is essential for tumor growth, invasion, and metastasis, and Marion- 
Audibert et al. reported the correlation between angiogenesis and survival with PNEN.
22
Measurement of the microvessel density (MVD) has been reported as a reliable marker 
for tumor angiogenesis. Therefore, evaluation of tumor angiogenesis by measuring the 
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MVD may be an important prognostic factor. However, the relationship between MVD 
and pathological grade or between MVD and enhancement on dynamic CT is unclear. 
We performed a retrospective study of a series of PNENs in order to determine 
whether quantitative evaluation of the enhancement on dynamic CT predicts the 
WHO2010 pathological grade. Additionally, we investigated the relationship between 
enhancement on enhanced CT, pathological grade, and quantitative evaluation of 
intratumoral MVD. 
To our knowledge, this is the first report to show a correlation between quantitative 
evaluation of enhancement on dynamic CT and pathological grade based on WHO2010 
and MVD. 
Methods 
Patients. In this retrospective study, we enrolled 39 patients who were diagnosed with 
PNEN by using histopathological or cytological analysis of samples obtained via 
EUS-FNA and/or operation samples at the Okayama University Hospital from 
December 2007 to March 2012. All 39 patients underwent dynamic CT and EUS-FNA. 
Surgery was performed for all G1 and G2 patients and for 2 of 6 (33%) G3 patients. 
These pathological samples were carefully examined by two pathologists (T.T and K.I) 
based on the WHO2010 classification. The tumor staging of all patients was performed 
using CT according to the European Neuroendocrine Tumor Society (ENETS) 
guidelines. 
CT protocol. Triphasic spiral CT was performed using MDCT (Aquilion; TOSHIBA, 
Tokyo, Japan). The scanning parameters were 120 kVp, 150 mAs, 2-mm section 
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collimation and an 11.0 mm/s table speed, during a single-breath-hold helical 
acquisition period of 20–25 s. Images were obtained in a craniocaudal direction and 
were reconstructed every 5 mm to obtain contiguous sections. The bolus tracking 
method was used for scanning in each patient. With a power injector, 2 mL/kg of 
nonionic iodinated contrast agent (iopamidol, Iopamiron 370; Shering, Berlin, 
Germany) was injected in the antecubital vein at a ﬂow rate of 4.0 mL/s. The arterial 
phase, portal venous phase, and delayed phase spiral scans were automatically started 
12, 32, and 180 s, respectively, after exceeding the contrast enhancement threshold level 
in the lumen of the descending aorta. 
Quantitative evaluation of dynamic CT. To evaluate the enhancement of tumor, we 
defined CT ratio as the ratio of CT value of the tumor to that of normal pancreatic 
parenchyma in the arterial phase. CT values were quantified by using Hounsfield unit 
thresholds by placing a region of interest (ROI) at three points. The ratio of each mean 
CT ratio of tumor to that of parenchyma was calculated. CT values were measured by 
one of the authors (N.Y), who was blinded to the clinical information. ROIs at the 
tumor were placed on the lowest density area with taking care to avoid the pancreatic 
duct and cystic lesion. 
EUS-FNA and pathological evaluation. We used a convex echoendoscope (UCT260; 
Olympus Optical Co. Ltd., Tokyo, Japan) connected to a US device (α10; Aloka, Tokyo, 
Japan). After detecting the objective tumor, we performed fine needle aspiration by 
using a 19-gauge, 22-gauge, or 25-gauge needle (EchoTip-Ultra needle; Cook Medical, 
Limerick, Ireland). The selection of diameter of needle depended on the tumor size and 
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the blood flow volume of the tumor. A part of the aspirated materials was immediately 
evaluated by using Diff Quick staining by a cytopathologist for rapid onsite evaluation 
(ROSE). After ROSE, the remaining material was fixed in 10% formalin in a specimen 
bottle. The specimens that were too small to assess as materials for histopathological 
diagnosis were centrifuged, and then embedded in paraffin for cell-block analysis. 
Sections were subjected to hematoxylin and eosin staining and immunohistochemical 
staining and were then evaluated by two independent pathologists (T.T and K.I). 
Hematoxylin and eosin staining and immunohistochemistry. The formalin-fixed 
specimens were processed into paraffin according to standard routine methods, and 
5-µm sections were stained with hematoxylin and eosin for conventional histology and 
were assessed as detailed in the WHO2010 guidelines. Immunohistochemistry was 
performed according to standard routine methods. We used the primary antibodies 
against CD31 (M0823; Dako Japan), chromogranin A (clone LK2H10), synaptophysin 
(clone SP11) (Automated Slide Preparation System BenchMark XT; Ventana Medical 
Systems Inc., Tucson, Ariz) and Ki-67 (clone MIB-1; Dako, Glostrup, Denmark). 
Primary antibodies were detected using secondary antibody (Dako Japan), and the 
signal was developed with diaminobenzidine, followed by hematoxylin counterstaining. 
Evaluation of MVD. To determine MVD, the tissue sections stained with CD31 were 
screened under low magnification (×40) and the most vascularized areas within tumors 
were selected; the three selected areas were photographed using a digital camera under 
high magnification (×100) (BX51 and DP50; Olympus, Tokyo, Japan). The recorded 
images had a resolution of 1 920,000 pixels. CD31 immunohistochemistry was 
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performed in all surgical samples of G1 and G2 cases and two resectable G3 cases. In 
the four unresectable G3 cases, CD31 immunohistochemistry was performed in 
EUS-FNA samples. To calculate the MVD, the areas occupied by CD31-positive 
microvascular was quantified using Adobe Photoshop (version CS6; Adobe Systems). 
The average MVDs of the three selected areas were calculated as percentages of the 
CD31-stained area in a field of tumor sections. The sections were independently scored 
by two observers (Y.N and K.T) blinded to the clinical data of the patients. 
Statistical analysis. Statistical analysis was performed using JMP8 (SAS, USA). 
Chi-square test or Student’s t- test were used to analyze variables. A probability of p < 
0.05 was considered statistically significant. 
Results 
Patients. Table 1 shows the clinical and histological characteristics of the patients. In 
our data, all G3 cases and 4 of 9 G2 (44%) cases had distant metastasis. Prediction of 
pathological grade depending on the presence of distant metastasis was not easy. All G1 
cases and 5 of 9 (56%) G2 cases underwent definitive operation. The remaining four G2 
patients with distant metastasis underwent debulking or bypass operation. Of six 
patients with G3, one underwent curative pancreaticoduodenectomy and another patient 
underwent only bypass operation because of peritoneal dissemination; the other four 
patients received chemotherapy after pathological diagnosis with EUS-FNA. 
Diagnostic ability of EUS-FNA. Thirty-five of 39 (90%) cases could be diagnosed 
with PNEN with EUS-FNA. Three of four cases could not be diagnosed correctly 
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because of lack of sufficient specimen. One case was misdiagnosed as sarcoma. The 
diagnosis rate for neuroendocrine neoplasm was 92%, 78%, and 100% for G1, G2, and 
G3 cases, respectively. Of the 35 cases diagnosed with PNEN by using EUS-FNA, 
pathological grade could be identified in only 15 (43%) cases. The pathological grade 
identification rate of EUS-FNA was 45%, 0%, and 83% for G1, G2, and G3 cases, 
respectively. 
Diagnostic ability of dynamic CT. Figure 1 shows that representative CT images of 
pathological grade 1, 2, and 3 at the artery phase. An expert radiologist checked the 
dynamic CT findings. Eighteen of 19 (95%) patients of typical hypervascular tumors 
were diagnosed correctly. Three of 13 (23%) hypovascular cases were misdiagnosed as 
pancreatic ductal carcinoma. Two of seven (29%) patients with slightly hypervascular 
cases were misdiagnosed with intraductal papillary mucinous carcinoma (IPMCa) or 
gastrointestinal stromal tumor (GIST). PNEN was aggressively suspected in 26 of 39 
(67%) cases based on clinical imaging findings on dynamic CT. Twenty of 26 (77%) 
cases were graded as G1, 5 (19%) as G2, and 1 of 6 (4%) as G3. 
Diagnostic ability of dynamic CT for CT ratio. ROIs were placed on the lowest 
density area while taking care to avoid the pancreatic duct and cystic lesion. In this 
study, we could not find necrotic tissue in any of the 39 patients. The CT ratio had 
significant correlation with each pathological grade (Supplemental Figure 1). The ratios 
in the G3 cases were significantly lower than those in the G1 and G2 cases (p = 0.0003) 
(Figure 2). The area under the receiver operating characteristic curve (AUROC) for 
prediction of G3 with CT ratio was 0.97 (Supplemental Figure 2). The sensitivity, 
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specificity, positive predictive value (PPV), negative predictive value (NPV), and 
diagnosis accuracy were 100%, 94%, 75%, 100%, and 95%, respectively with the 
cut-off value of CT ratio, 0.75, by the ROC analysis. 
Correlation between MVD and CT value ratio. Three examples of CD31 
immunostaining of PNEN are shown in Figure 3. The brownish area is the 
CD31-positive area (magnification: ×100). Figure 3A shows G1 PNEN. Intratumoral 
MVD is high, and the length of microvessels is long. Figure 3B shows G2 PNEN. The 
MVD of G2 is lower than that of G1, and the length of microvessels is shorter than that 
of G1. Figure 3C shows G3 NEN. MVD is very low and almost no microvessel can be 
seen in G3. MVD has a significant correlation with CT ratio (r = 0.83, p < 0.0001) 
(Figure 4) and pathological grade (p = 0.0074) (Figure 5). 
Discussion 
The prognosis of PNEN differs depending on pathological grade and is unfavorable in 
patients with G3 disease.
2,4,5,7,8,11
 Some effective therapies are reported in unresectable
G1 and G2 cases,
9–11
 but in G3 cases, which are almost always unresectable, the
prognosis is unsatisfactory.
9
 Therefore, pathological grading is a very important factor
for deciding the therapeutic strategy, and in the surgical resection cases, it is easy to 
obtain enough samples for pathological grading. 
In our study, 4 of 9 (44%) G2 cases (three, liver metastasis; one, liver and bone 
metastasis) and 5 of 6 (83%) G3 cases had distant metastasis of the liver (Table 1). 
Therefore, the presence or absence of distant metastasis does not always have a 
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relationship with pathological grade. It is also very important to diagnose pathological 
grade in unresectable cases because of distant metastasis or other reasons. 
The usefulness of EUS-FNA for the diagnosis of PNEN has been reported in many 
papers, and its accuracy has been estimated at 83–93%.
23–26
 In our study, 35 of 39 (90%)
cases were diagnosed as PNEN. We also verified whether the EUS-FNA is useful for 
prediction of pathological grade per the WHO2010. Ten of 29 (34%) G1 and G2 cases 
and 5 of 6 (83%) G3 cases were accurately predicted using EUS-FNA. Except for five 
unresectable cases that were diagnosed as grade 3 with EUS-FNA samples because of 
the high Ki67 index, EUS-FNA samples were checked against the surgical samples. 
There was one case, which, at first, was determined as G1 via EUS-FNA, but was 
finally determined to be G3 after assessing the surgical sample. In this case, inadequate 
specimen with EUS-FNA misled the pathological grading. Previous studies have 
described the strong ability of EUS-FNA to predict pathological grade,
15,27–29
 but there
was no proof of surgical sample or exact validation between FNA and surgical 
samples,
15,27,28
 or there was a discrepancy in the Ki67 labeling between the cytological
and surgical samples, except for high Ki67 labeling.
29
 In cases of a discrepancy in Ki67
labeling between EUS-FNA and surgical samples, pathological evaluation using 
EUS-FNA samples may not provide accurate findings. Hasegawa et al. stated that 
concordance rates of pathological grade between EUS–FNA samples and resected 
specimens are 74.0% when using the mean Ki-67 index in EUS–FNA specimens and 
77.8% when using the highest Ki-67 index. 
14 In addition, the concordance rate rises
to 90% when EUS–FNA samples with less than 2000 tumor cells are excluded. 
However, it is often difficult for an unskilled endoscopist to obtain more than 2000 
tumor cells. In addition, it is also difficult to obtain information on the number of cells 
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from on-site examination, and repeated needling for obtaining enough tumor cells may 
sometimes result in complications such as bleeding. These results suggest that diagnosis 
of PNEN is possible by using EUS-FNA, but pathological grading is often difficult. In 
our study, the diagnosis rate of pathological grade was low (43% for all pathological 
grades). Therefore, the diagnosis rate using EUS-FNA samples might depend on the 
technical level, which may lead to variation between facilities. 
PNEN shows varied enhancement on dynamic CT.
17–21,30
 As shown in Figure 1A,
tumors with typical findings are easy to diagnose, but some neoplasms cannot be 
differentiated from pancreatic adenocarcinomas.
31
 Therefore, the diagnostic accuracy of
dynamic CT is insufficient, with 64–81% of sensitivity.
32
 In our study, only 67% of
patients could be initially diagnosed with suspected PNEN on dynamic CT alone. All 
tumors diagnosable by CT are hypervascular (Figure 1A), whereas hypovascular tumors 
(Figure 1B, 1C) are difficult to diagnose. This shows that dynamic CT alone is not 
always useful for diagnosis of PNEN. 
We found a correlation between WHO2010 pathological grade and enhanced effect 
on dynamic CT. There was an evident negative correlation between CT ratio and 
pathological grade (p < 0.05) (Supplemental Figure 1), in particular G3 (Figure 2). 
Some reports have shown that tumor-to-pancreas contrast is usually greatest in the 
arterial phase in PNEN cases.
17,18,20,31
 Therefore, we used arterial phase images to
evaluate the enhancement and calculate the CT ratio. By using ROC curve analysis to 
understand the association between CT ratio and pathological grade, the cut-off value of 
CT ratio value was calculated. Based on this cut-off value of 0.75, pathological G3 
could be accurately identified with significant probability. We believe that CT ratio is 
extremely useful for prediction of pathological grade. CT ratio does not rely on 
Page 23 of 31 Journal of Gastroenterology and Hepatology
For Peer Review
14 
technical skills, which would reduce the differences across facilities. CT ratio was also 
significantly correlated with tumor size. CT ratio was higher in smaller tumors (p = 
0.016) (Supplementary Figure 3). Moreover, tumor size was significantly correlated 
with pathological grade. In G3 patients, tumor size (median size: 41 mm) was larger 
than in G1 and G2 patients (median size: 20 mm) (p = 0.029) (Supplementary Figure 4). 
However, tumor size is not useful for predicting the pathological grade. The sensitivity, 
specificity, PPV, NPV, and diagnosis accuracy were 83%, 67%, 31%, 96%, and 69%, 
respectively, with a cut-off value of tumor size of 30 mm by the ROC analysis 
(Supplementary Figure 5). 
By using pathological samples, we found that the decrease in the CT ratio was 
significantly correlated with decreased MVD (Figure 4). The correlation between 
enhanced effect in dynamic CT and MVD has been reported in lung cancer,
33
 hepatic
cellular carcinoma,
34
 pancreatic ductal adenocarcinoma,
35
 prostate disease,
36
 and
mammary adenocarcinoma.
37,38
 Moreover, one study showed that MVD decrease is a
predictive factor of prognosis, and MVD has significant negative correlation with Ki67 
index in PNEN.
22
 In that study, Marion-Audibert et al. showed that well-differentiated
neuroendocrine neoplasms can induce the maintenance of organoid features in their 
microenvironment, including a high microvascular density recalling the situation in the 
normal pancreatic neuroendocrine tissue. Thus, the MVD has a significant relationship 
with the Ki67 index, and it is a very important factor in the clinical course of this 
disease. Our research shows MVD had a correlation with CT ratio (Figure 4) and 
pathological grade (Figure 5). These results indicate that MVD is high in G1, low in G3, 
and intermediate in G2, and CT ratio can reflect the MVD in each pathological grade. 
Therefore, we believe that CT ratio in dynamic CT is useful for predicting the 
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pathological grade. 
In conclusion, CT ratio in dynamic CT is related to pathological grade in PNEN. 
Moreover, we identified a relationship between CD31 expression in the tumor and 
pathological grade. CT ratio is thought to reflect MVD, and prediction of pathological 
grade with dynamic CT ratio is possible. After diagnosis of PNEN with EUS-FNA, CT 
ratio with dynamic CT is very useful for predicting the pathological grade of PNEN. In 
this way CT ratio is very useful to decide the therapeutic strategy, in particular for 
unresectable cases in which adequate sample is difficult to obtain for pathological 
grading. To our knowledge, this is the first report that states that there is a correlation 
between quantitative evaluation of enhancement on dynamic CT, pathological grade 
based on WHO2010, and MVD. 
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Supplemental Figure 3  
The relationship between CT ratio and tumor size. CT ratio is higher in smaller tumors (p = 0.016, r = -
0.38). 
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Supplemental Figure 5  
Receiver operating characteristic (ROC) curve for prediction of G3 with tumor size. The cut-off value of 
tumor size between the G1, G2, and G3 determined by the ROC analysis was 30mm.  
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